RA0721

antibody from Oursmab

Targeting: TGFB1 CED, DPD1, TGFB, TGFbeta

Western blot (Supportive data in Antibodypedia)

ELISA (Supportive data in Antibodypedia)

Immunocytochemistry (Recommended by provider)

Flow cytometry (Recommended by provider)

Functional assay (Recommended by provider)

Antibody Data

Product number

RA0721

Provider

Oursmab

Product name

Metelimumab (Biosimilar Reference Antibody) (TGFB1)

Antibody type

Monoclonal

Description

Metelimumab is a fully human monoclonal antibody that specifically targets transforming growth factor-beta 1 (TGF-¦Â1), a key profibrotic cytokine. By binding to TGF-¦Â1, it neutralizes the cytokine and prevents it from interacting with its receptors, thereby blocking downstream Smad-dependent signaling pathways that drive fibroblast activation, collagen production, and tissue fibrosis. It was developed as a potential anti-fibrotic therapy and was clinically evaluated for the treatment of diffuse cutaneous systemic sclerosis (scleroderma), a disease characterized by excessive collagen deposition and progressive skin thickening. However, its development was discontinued due to lack of efficacy in Phase II trials.

Reactivity

Human

Isotype

IgG

Vial size

100 ¦Ìg,1 mg,5 mg-500,10 mg,25 mg,50 mg,530 mg

Concentration

Bottled at the concentration indicated on the vial.

Storage

Store at -20¡ãC or -80¡ãC. Avoid repeated freeze.

Western blot

Supportive validation

Submitted by

Oursmab (provider)

Main image

Experimental details

Metelimumab (Biosimilar Reference Antibody) (TGFB1)-RA0721-Oursmab determined by SDS-PAGE. The purity of the protein is greater than 98%.

ELISA

Supportive validation

Submitted by

Oursmab (provider)

Main image

Experimental details

ELISA plate pre-coated Antigen protein, can bind Metelimumab (Biosimilar Reference Antibody) (TGFB1)-RA0721 in a linear range of 15.63¨C125 ng/mL.